Tirzepatide has not been shown to cause cancer in humans. Clinical trials lasting up to 72 weeks found no increased risk of overall or specific cancers compared to placebo or other diabetes treatments. However, the drug does carry a prominent FDA warning about thyroid tumors found in animal studies, which is the likely reason you’re seeing this concern online. Here’s what the evidence actually shows.
The FDA’s Thyroid Tumor Warning
Both Mounjaro and Zepbound (the brand names for tirzepatide) carry the FDA’s most serious type of label warning, called a boxed warning, about thyroid C-cell tumors. In rats, tirzepatide caused thyroid tumors at doses comparable to what humans take, and the risk increased with higher doses and longer treatment. The specific concern is a rare type of thyroid cancer called medullary thyroid carcinoma (MTC), which originates in the C-cells of the thyroid gland.
The critical line in the warning: “It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.” This isn’t the FDA saying it probably does. It’s saying the animal data raised a flag that hasn’t been confirmed or ruled out in people yet.
Why Rodent Results May Not Apply to Humans
The thyroid tumors in rats are triggered through a specific biological pathway. Tirzepatide activates receptors for GLP-1, a gut hormone involved in blood sugar regulation and appetite. Rat thyroid C-cells have high levels of these GLP-1 receptors. When the drug stimulates those receptors over long periods, it causes the cells to overgrow, eventually leading to tumors. Studies in mice confirmed this directly: animals genetically engineered to lack GLP-1 receptors did not develop these thyroid changes, while normal mice did.
Human thyroid tissue is fundamentally different. GLP-1 receptor levels in normal human thyroids are low or absent. Studies in non-human primates (whose thyroid biology is closer to ours) also did not show the same C-cell effects seen in rodents. Additionally, the pathway the drug activates in rodent C-cells is completely separate from the genetic mutation that typically drives medullary thyroid cancer in humans. In rodents, the tumors arise through a growth-signaling pathway called mTOR. In humans, MTC is usually linked to mutations in a different gene called RET. Tirzepatide does not activate RET.
This species difference is why the FDA warning says “unknown” rather than “likely.” The same boxed warning appears on every GLP-1 receptor agonist on the market, including semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda). It’s a class-wide precaution based on rodent data, not a signal from human patients.
What Clinical Trials Found
A 2025 systematic review and meta-analysis pooled data from randomized controlled trials of tirzepatide, covering thousands of participants followed for 26 to 72 weeks. The results were straightforward: tirzepatide did not increase the overall risk of cancer compared to placebo, insulin, or other GLP-1 drugs.
The researchers also looked at individual cancer types. Breast cancer showed no increased risk, with a relative risk of 0.59 compared to control groups, meaning tirzepatide users actually had fewer cases, though the difference wasn’t statistically significant. Pancreatic cancer, another concern that sometimes comes up with diabetes drugs, also showed no increased risk. None of the specific cancer types analyzed were more common in people taking tirzepatide.
These trials do have a limitation: the longest ran about 18 months. Cancer often takes years or decades to develop, so these results can’t speak to very long-term risk. But for the timeframes studied, there is no cancer signal.
Possible Protective Effects
Interestingly, some research suggests GLP-1 drugs as a class might lower the risk of certain cancers. A large retrospective study found that people taking a GLP-1 receptor agonist were 36% less likely to develop colorectal cancer than those taking aspirin, which itself has a known protective effect. The absolute benefit for any one person was small, but across millions of users, the numbers could be meaningful. This research is still in early stages and hasn’t been established specifically for tirzepatide, but it adds context to the overall safety picture.
Who Should Not Take Tirzepatide
Despite the reassuring human data so far, tirzepatide is strictly off-limits for certain people. You should not use it if you have a personal or family history of medullary thyroid carcinoma, or if you have a genetic condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). MEN 2 is a rare inherited disorder that dramatically increases the risk of MTC, and adding a drug with even a theoretical thyroid concern on top of that predisposition is not considered safe.
If you’re taking tirzepatide, be aware of symptoms that could suggest thyroid problems: a lump or mass in your neck, difficulty swallowing, shortness of breath, or persistent hoarseness. The FDA notes that routine screening with blood tests or thyroid ultrasound hasn’t been shown to reliably catch MTC early in people on these drugs, so paying attention to symptoms matters more than chasing screening tests.